Supply chain and price components of antimalarial medicines: Uganda 2007

Abstract

This study, led by the Medicines for Malaria Venture in collaboration with the Ministry of Health Uganda, HEPS and WHO, investigated what components make up the final retail price of 8 antimalarials in Uganda and 5 other essential medicines. Investigations were carried out in 2007 in Kampala, in a rural area with little pharmaceutical supply chain infrastructure, and in an intermediate area. It was found that: the importer, wholesaler and retailer add the main price components, which have a cumulative impact; the mark-ups added at each stage vary greatly between sectors and regions; the supply chain is more complex in rural areas; the manufacturer's selling price often makes only a small contribution to the final price; locally produced products are similar in price to imported ones; retail mark-ups make the greatest contribution to final price; marketing practices and affordability can affect mark-ups; and the overall mark-up varies between 120% and 375% depending on the outlet. Recommendations are made for improving the situation. [See also the previously published report 'Understanding the antimalarials market: Uganda 2007 – An overview of the supply side'].

Citation

Published by Medicines for Malaria Venture, Geneva, Switzerland, 2008; 34 pp.

Supply chain and price components of antimalarial medicines: Uganda 2007

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.